Stable Dietary Ora-Curcumin Formulation Protects from Experimental Colitis and Colorectal Cancer

Area of Science:

• Gastroenterology and Oncology
• Drug Delivery and Formulation Science

Background:

• Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are significant health concerns with limited therapeutic options.
• Existing curcumin therapies face bioavailability challenges due to poor solubility, rapid metabolism, and instability.
• There is a critical need for improved therapeutic strategies for IBD and CRC.

Purpose of the Study:

• To develop and evaluate OC-S, a novel water-soluble and colon-targeted curcumin formulation.
• To assess the stability, compatibility, and targeted retention of OC-S in inflamed colon tissue.
• To investigate the in vivo and in vitro efficacy of OC-S against colitis and colorectal cancer.

Main Methods:

• Development of OC-S, a water-soluble, colon-targeted curcumin formulation.
• Assessment of OC-S stability and compatibility with commercial dietary products.
• In vivo studies using a murine model of colitis and in vitro studies with colon cancer tumoroids.
• Evaluation of OC-S binding to inflamed colon tissue and its anti-inflammatory and anti-proliferative effects.

Main Results:

• OC-S demonstrated stability and compatibility with various dietary products.
• OC-S exhibited specific binding to inflamed colon tissue, enhancing retention at the site of inflammation.
• OC-S significantly reduced colitis severity and pro-inflammatory cytokine expression compared to curcumin, even at low doses.
• OC-S showed superior anti-proliferative activity against CRC cells and tumoroids compared to curcumin.

Conclusions:

• OC-S effectively delivers curcumin to inflamed colon sites, improving bioavailability and therapeutic potential.
• OC-S demonstrates significant efficacy in treating colitis and inhibiting colorectal cancer progression.
• OC-S shows promise as a dietary supplement for managing both IBD and CRC, warranting further clinical development.